We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Adults with obesity who regained weight ...

The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors cut the risk for adverse CV outcomes ...

"Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes" was originally created and published by Clinical ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...

Credit: Getty Images. The Company is currently investigating TAK-994 in adults with narcolepsy type 1 or type 2 in a phase 2 study. The Food and Drug Administration (FDA) has granted Breakthrough ...

A new global review has found that receiving Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependence. The review found that people ...

Patients with diabetes being managed with GLP-1R agonists can expect a slight decrease in intraocular pressure. Glucagon-like peptide-1 receptor (GLP-1R) agonist therapy used for the treatment of ...

Few patients with opioid toxicity receive opioid agonist therapy (OAT), data suggest. In a retrospective study that examined about 21,000 hospital visits related to opioid use disorder (OUD) in ...

In the week following any hospital visit for an overdose, only 1 in 18 people with opioid use disorder begin a treatment known to be highly effective in reducing illness and deaths, according to new ...